Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595071 | 0.84 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| Hydrochloric Acid SCHEMBL6593571 | 0.82 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL7457314 | 0.79 | CSNK2A1 (0.37) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL28267566 | 0.79 | ALDH1A1 (0.36) | ALDH1A1CYP3A4CSNK2A1ESR1ESR2 | |
| SCHEMBL27790126 | 0.72 | ERN1 (0.40) | ALDH1A1ESR1ESR2 | |
| SCHEMBL27537789 | 0.71 | CNR2 (0.39) | ALDH1A1CYP3A4ADORA2A | |
| SCHEMBL27295193 | 0.71 | ADORA3 (0.36) | ALDH1A1FYNESR1ESR2ADORA2A | |
| SCHEMBL8055265 | 0.70 | ESR1 (0.39) | ALDH1A1CYP3A4CSNK2A1FYNESR1 | |
| SCHEMBL27605327 | 0.69 | CNR2 (0.35) | ALDH1A1ESR1ESR2ADORA2APOLB | |
| SCHEMBL7461800 | 0.69 | CYP3A4 (0.41) | ALDH1A1CYP3A4TSHRTDP1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544981-B2 | Anticoagulants, cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1294716-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | Bristol-Myers Squibb Company (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2001096331-A1 | LACTAM INHIBITORS OF FACTOR XA AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025957-A1 | Lactam inhibitors of factor Xa and method | F9, F7, F11 | ALDH1A1 2640/4885CYP3A4 190/4885TSHR 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.